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Abstract: In order to expand hepatitis C virus (HCV) screening, a change in the diagnostic paradigm
is warranted to improve accessibility and decrease costs, such as utilizing dried blood spot (DBS)
collection. In our study, blood from 68 patients with chronic HCV infection was spotted onto DBS cards
and stored at the following temperatures for one week: −80 ◦C, 4 ◦C, 21 ◦C, 37 ◦C, and alternating
37 ◦C and 4 ◦C; to assess whether temperature change during transportation would affect sensitivity.
Sample was eluted from the DBS cards and tested for HCV antibodies (HCV-Ab) and HCV core
antigen (core-Ag). HCV-Abs were detected from 68/68 DBS samples at−80 ◦C, 4 ◦C, 21 ◦C, and 67/68 at
37 ◦C and alternating 37 ◦C and 4 ◦C. Sensitivity of core-Ag was as follows: 94% (−80 ◦C), 94% (4 ◦C),
91% (21 ◦C), 93% (37 ◦C), and 93% (37 ◦C/4 ◦C). Not only did temperature not greatly affect sensitivity,
but sensitivities are higher than previously reported, and support the use of this assay as an alternative
to HCV RNA. We then completed a head-to-head comparison (n = 49) of venous versus capillary
samples, and one versus two DBS. No difference in core-Ag sensitivity was observed by sample
type, but there was an improvement when using two spots. We conclude that HCV-Abs and core-Ag
testing from DBS cards has high diagnostic accuracy and could be considered as an alternative to
HCV RNA in certain settings.
Keywords: Chronic hepatitis C; dried blood spot; core-antigen; diagnosis; widespread screening
1. Introduction
Therapeutic developments have revolutionized the treatment of hepatitis C virus (HCV) infection
and raised the prospect of global elimination. Despite this progress, HCV continues to have low rates
of diagnosis, partially due to complicated diagnostic algorithms. The most widely used approach
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is the two-assay format that detects HCV antibodies (HCV-Abs), followed by viral RNA to confirm
current infection [1]. Although both assays can be done from a single sample, most laboratories require
two samples for reflex testing, or a follow-up sample, which has been cited as a barrier in the HCV
cascade of care (reviewed in Reference [2]). Alternatively, a measure of active infection could be done
as the initial test, however the cost of HCV RNA is often prohibitive. HCV core antigen (core-Ag)
is an alternative marker of infection with high specificity, and correlates well with HCV viral load.
The clinical sensitivity of the assay is excellent; however, the analytical sensitivity is unreliable below
3–10 fmol/L (RNA viral load of 1000–3000 IU/mL) [3]. Nonetheless, as most individuals with chronic
HCV infection have RNA levels above this threshold, core-Ag is an effective and less expensive tool for
confirmation of active infection [4].
In many high-income countries, up to half of chronic infections remain undiagnosed and diagnosis
rates in low- and middle-income countries are much lower [5–7]. The low diagnosis rates are due to
the generally asymptomatic nature of the disease, the reliance on risk factor-based testing, and in some
settings, limited access to healthcare infrastructure and the high cost of HCV diagnostic tests [8,9].
Among high-risk populations, additional barriers to testing exist. For people who inject drugs, standard
venipuncture may be particularly challenging. The need for trained staff to draw venous blood limits
peer testing and other approaches that may help engage people who may have experienced stigma in
healthcare settings [10]. The requirement to come back for a second test is a major additional barrier,
with 30–40% of persons who test HCV antibody positive never returning to confirm viremia, let alone
to engage in care and treatment [11,12]. Dried blood spot (DBS) testing has been shown to overcome
some of these challenges and is widely used in other diseases [13]. As only a finger-prick is needed,
the requirement for venous access is eliminated, allowing those without healthcare training to perform
sample collection. Furthermore, subsequent testing can be reflexively completed from the same card.
The HCV core-Ag assay from DBS could provide a less expensive alternative to HCV RNA testing
for active infection, however, there have been few studies that have assessed the sensitivity and
quantification of core-Ag from DBS, and those that have do not have consistent collection or processing
methods. Furthermore, the effects of storage conditions are not known [14]. The aim of this study was
to determine whether testing core-Ag from DBS could be used to diagnose chronic HCV infection;
and whether storage temperature influences diagnostic sensitivity and the correlation between core-Ag
from serum and DBS. In follow-up we determined whether sensitivity differed when using venous
versus capillary blood, as well as one versus two dried blood spots.
2. Materials and Methods
2.1. Study Population and Design
Patients with chronic HCV infection visiting the outpatient clinic of the Toronto Centre for Liver
Disease (TCLD) (Toronto, Canada) were approached from June 2015 to December 2018. All HCV-positive
persons included in the study had a detectable viral load as determined clinically at Public Health
Ontario by the Roche Cobas AmpliPrep TaqMan HCV Assay, and were either treatment-naïve or
were classified based on their prior treatment history. Clinical and demographic data were collected
from the electronic medical record. To assess the specificity of DBS, known HCV-negative controls
were included. Staff carrying out the testing of DBS samples were blinded to the HCV status of the
tested individuals.
2.2. Dried Blood Spots (DBS) and Serum Sample Collection
In order to assess overall sensitivity and the effect of storage conditions, two tubes of venous
blood were collected from HCV-infected individuals and negative controls. One tube was used to
fill five spots of 50 µL per spot to a Munktell-TFN protein saving DBS cards (Ahlstrom Germany,
Bärenstein, Germany). The spotted DBS cards were left to dry overnight at room temperature and
were then inserted into an individual plastic bag containing a desiccant pack. Each DBS card was
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subsequently stored under a different condition for one week to simulate issues that may arise during
sample collection and transport: (1) −80 ◦C (gold standard), (2) 4 ◦C (refrigeration rather than freezing),
(3) 21 ◦C (storage at room temperature rather than freezing), (4) 37 ◦C (storage in high temperature
environments) and (5) three days of alternating 12 h at 37 ◦C and 12 h at 4 ◦C (variable temperatures
during transport). Following the experimental storage conditions, the DBS cards were stored at −80 ◦C
until elution. The second tube of venous blood collected was stored at −80 ◦C for serum core-Ag testing.
In order to evaluate the effect of capillary blood collection in comparison to venous blood, one tube
of venous blood was collected from patients with chronic HCV infection and HCV Ab-negative
individuals. This tube was used to spot 75 µL of blood per spot to six spots on two Munktell-TFN
protein saving DBS cards (Ahlstrom Germany, Bärenstein, Germany). Additionally, three dried blood
spots were filled by capillary blood from a finger-prick sample from the same individual. The spotted
DBS cards were left to dry overnight at room temperature and were then inserted in an individual
plastic bag containing a desiccant pack. Each DBS card was subsequently stored at −80 ◦C until elution.
2.3. Dried Blood Spots (DBS) Anti-Hepatitis C Virus (HCV) and Core-Antigen (Ag) Elution and Testing
After storage at −80 ◦C, the individual spots were cut out and inserted into a microtube containing
0.8 mL of 0.25% TX-100 phosphate-buffered saline (PBS) for elution. 400 µL was used for testing; or in
the optimized protocol 0.8 mL for one, two, or three spots (three for venous only). Microtubes were
gently shaken and incubated at room temperature for 90 min. Spots were then removed, and the
elution product was stored at −80 ◦C until diagnostic testing. HCV-Abs were tested using the Architect
i4000 SR (Abbott, Chicago, Illinois) with a lower limit of detection (LLOD) of 1.00 S/CO and core-Ag
was tested by the HCV ARCHITECT core antigen assay (Abbott, Chicago, Illinois) with a LLOD of
3 fmol/L. In this assay values of 3–10 fmol/L are diagnostically positive (grey-zone), but the lower limit
of quantification is 10 fmol/L. Thus, only samples that were determined to be greater than 10 fmol/L
were correlated to the patient’s viral load. However, all samples greater than 3 fmol/L were included
for determination of sensitivity.
2.4. Statistical Analysis
Data are presented as medians with interquartile range (IQR) or means with standard deviations
(SD). Sensitivity was calculated to determine diagnostic accuracy. Quantitative data were compared
using a paired t-test. Correlation between quantitative samples was assessed using Pearson’s correlation
coefficient after log transformation. Analysis and graphing were completed using Prism GraphPad
(version 7).
2.5. Ethics
The study protocol was conducted in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines and was originally approved on the 16th of December 2014 by the University
Health Network Ethics Review Board (UHN REB 14-8383).
3. Results
3.1. Patient Characteristics
A total of 117 patients with chronic HCV infection, and 15 HCV-Ab negative patients were included.
Within the 15 negative controls, five were healthy individuals, and 10 were infected with hepatitis
B virus (HBV). Patient characteristics are summarized in Table S1. The majority of the cohort was
male (59.0%), and non-cirrhotic (70.9%). The most frequently identified genotype was genotype (GT) 1
(65.8%), although other genotypes were also reported. With respect to treatment status, 89 (76.1%)
patients were treatment-naïve, 24 (20.5%) were prior non-responders or had relapsed, and 4 (3.4%)
discontinued therapy due to adverse events.
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3.2. Detection of Core-Antigen (Ag) Is Unaffected by Changes in Storage Temperature
Testing algorithms for HCV include screening samples for the presence of HCV Abs, followed by
a confirmatory assay to establish active infection. In our study, HCV-Abs were detected from DBS
in all HCV-infected patients in all conditions, except for one patient in whom HCV-Abs were not
detected from a DBS card stored at 37 ◦C and at 37 ◦C/4 ◦C (Table 1). Next, we examined whether
temperature affected core-Ag detection. Storage at −80 ◦C and 4 ◦C had the highest sensitivity at
94.1% (95% CI 88.5–99.7%), and overall differences in sensitivity between conditions were minimal
ranging from 91.2–94.1%. However, in 4 samples there were conditions in which quantitative results
were in, or slightly above the grey-zone (3–10 fmol/L) for certain conditions, but below the LLOD for
others. In only one of these scenarios was there a pattern with hypothesized degradation based on
temperature, i.e., positive in −80 ◦C, 4 ◦C, 25 ◦C, and negative at 37 ◦C and 37/4 ◦C. When analysis
was performed using the quantification cutoff value of ≥10 fmol/L, detection ranged from 80.9–85.3%.
All HCV-negative controls tested negative for core-Ag from DBS under all storage conditions. Sensitivity
for all five storage conditions from DBS is shown in Table 1.
Table 1. Sensitivity and specificity of hepatitis C Virus (HCV) antibody and antigen on dried blood
spots (DBS) by storage condition.
Storage Condition HCV Antibody HCV Core Antigen
Sensitivity (95% CI)
n = 68
Sensitivity >3 fmol/L (95% CI)
n = 68
Sensitivity >10 fmol/L (95% CI)
n = 68
−80 ◦C 100% (100–100) (68/68) 94.1% (88.5–99.7) (64/68) 85.3% (76.4–94.2) (58/68)
+4 ◦C 100% (100–100) (68/68) 94.1% (88.5–99.7) (64/68) 85.3% (76.4–94.2) (58/68)
+21 ◦C 100% (100–100) (68/68) 91.2% (84.3–98.1) (62/68) 80.9% (70.8–91.0) (55/68)
+37 ◦C 98.6% (96.6–100) (67/68) 92.7% (86.4–98.9) (63/68) 80.9% (70.8–91.0) (55/68)
+37 ◦C/+4 ◦C 98.6% (96.6–100) (67/68) 92.7% (86.4–98.9) (63/68) 85.3% (76.4–94.2) (58/68)
3.3. Quantitative Analysis of Core-Antigen (Ag) from Dried Blood Spots (DBS)
Quantification of HCV viral load may have utility in treatment decisions. Therefore, we investigated
the correlation between serum core-Ag levels and HCV RNA. As shown in Figure S1, we determined
that core-Ag concentration in serum significantly correlated with HCV-RNA concentration in serum
(r = 0.76 (95%CI 0.63–0.84), p < 0.0001). Based on the serum viral RNA, one sample was predicted to be
below the LLOD based on established cut-offs for serum core-Ag (1000–3000 IU/mL). Additionally,
concordance between DBS duplicates for detection of HCV-Abs and detection of core-Ag was calculated
and ranged from 96–100% depending on storage condition (Table S2). Agreement when using a core-Ag
quantitative cut-off of 10 fmol/L is also shown (Table S2).
Interestingly, mean core-Ag concentration in serum was 1.7–1.9 log higher than core-Ag
concentration from DBS irrespective of the storage condition (p < 0.0001) (Figure 1). There was also
a statistically significant difference between mean values of samples stored at −80 ◦C in comparison
to samples stored at 37 ◦C and 37/4 ◦C (p < 0.05). The correlations between core-Ag concentration in
serum and DBS for the different conditions varied and demonstrated a statistically significant moderate
to strong positive correlation. As a representative example, a correlation graph for −80 ◦C including
all samples is shown in Figure 2A, r = 0.71. R-values were as follows for the various conditions:
r = 0.76 (−80 ◦C, Figure 2B), 0.71 (4 ◦C, Figure 2C), 0.73 (21 ◦C, Figure 2D), 0.45 (37 ◦C, Figure 2E), 0.60
(37 ◦C/4 ◦C, Figure 2F).
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3.4. Core Antigen (Ag) Sensitivity Is Increased by Dried Blood Spots (DBS) Number
Several groups have assessed the sensitivity of core-Ag from DBS using different sample collection
methods and sample processing conditions with variable sensitivity reported [15–17]. We investigated
whether the collection method (venous blood vs. finger-prick blood) and number of spots eluted (one vs.
two) from the DBS card affected assay sensitivity. As we demonstrated that storage temperature
does not significantly affect sensitivity, for this analysis all cards were stored at −80 ◦C until elution.
Sensitivity for both sample types and number of dried blood spots are shown in Table S3. For diagnostic
sensitivity, i.e., >3 fmol/L results were as follows: for both one venous sample spot and one finger-prick
spot sensitivity was 91.8% (95% CI 84.2–99.5%); for two venous sample spots and two finger-prick
spots sensitivity was 93.9% (95% CI 87.2–100%). There were 3 samples for which core-Ag was not
detected across all four conditions. The first sample was below the limit of detection of 3000 IU/mL
with a viral load of 1710 IU/mL. The other two samples had serum HCV RNA levels of 13,300 and
47,200 IU/mL; which were confirmed by chart review as chronic infections (despite low viral loads).
In addition, in two other samples, results went from undetectable (<3 fmol/L) to detectable
(>3 fmol/L) when two spots were used instead of one. The first of the two was above the LLOD in
one and two DBS blotted by finger-prick, however, when the sample was collected by venipuncture,
only the sample eluted from two spots was above the LLOD. In the second patient, the opposite was
true, where samples from both one and two DBS from venous blood were above the LLOD, but two
spots were necessary for positive detection from the finger-prick sample.
In those that were undetectable across all four conditions, no change in sensitivity was observed
when a third venous spot was used (data not shown). In both capillary and venous samples, quantitative
data for two dried blood spots was approximately two-fold that of one DBS: venous 1.95-fold
(SD +/− 0.35); finger-prick 1.97-fold (SD +/− 0.44). All 10 known HCV Ab negative samples were
correctly identified as negative.
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condition. Pearson correlation: (A) Samples stored at−80 ◦C. Samples excluded if core-Ag concentration
was less than 3 fmol/L stored at (B) −80 ◦C, (C) 4 ◦C, (D) 21 ◦C, (E) 37 ◦C, (F) 37 ◦C/4 ◦C.
There was a strong correlation in the quantitative analysis between venous and finger-prick
samples. As is shown in Figure 3, this was observed when comparing one spot of venous blood to
finger-prick r = 0.97 (95%CI 0.94–0.98), and when comparing two spots of venous to finger-prick
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whole blood r = 0.98 (95%CI 0.96–0.99). Next, we compared one versus two DBS from finger-prick
samples, which had been stored at −80 ◦C as these are the more clinically relevant sample type.
Our findings demonstrate that there is a strong positive correlation between two DBS samples blotted
from finger-prick in comparison to HCV RNA from serum, r = 0.9 (Figure 3C), as there is for a single
DBS (data not shown).
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4. Discussion
Identifying HCV cases requires a two-tiered testing algorithm involving detection of HCV-Abs
and HCV-RNA (or another marker of active infection such as core-Ag). Testing from DBS has been
recommended as a promising alternative to testing from plasma or serum in recent guidelines from
the WHO. The sensitivity and specificity of HCV-Ab testing from DBS is 98% and 99%, respectively,
while HCV RNA testing from DBS has a sensitivity of 96% and a specificity of 98% [18]. However,
to date the use of HCV core-Ag from DBS as a diagnostic assay for HCV infection has not been
recommended due to the limited data assessing the sensitivity and utility in real-world settings.
Our study lends support for this platform as an option for diagnosing chronic HCV infection, and in
fact shows increase sensitivity compared to other studies (Table 2).
The sensitivity of antibody testing demonstrated here is in agreement with results published
previously [16,19], and none of our HCV-negative controls tested positive for either HCV-Ab or core-Ag
from DBS. Although the number of HCV-negative controls was very limited, the specificity of HCV-Abs
and core-Ag from DBS has been reported elsewhere [16,17]. There was good concordance between
duplicates for antibody and antigen from a diagnosis perspective, demonstrating that duplicate testing
is not necessary.
Our study focused on individuals with detectable viral load in a clinical setting for the purposes
of diagnosing chronic infection, as case-finding remains a major challenge in the elimination of HCV
globally, hindered by collection difficulties and high costs of testing. Other studies have also evaluated
the use of core-Ag from DBS to confirm undetectable RNA. Soulier et al. assessed 26 patients with
known resolved infection as defined by the authors as either acutely clearing (n = 13) or SVR (n = 13),
and confirmed that core-Ag was undetectable in all cases (specificity of 100%) [16]. Moreover, a recent
study demonstrated that HIV or hepatitis B virus co-infection did not affect the sensitivity of core-Ag
testing from DBS [15].
In our hands, we observed that serum had a lower limit of detection than DBS. A similar
phenomenon was observed with HCV RNA, relating primarily to sample volume [20]. There was
a correlation between quantitative core-Ag measurements between serum and DBS, particularly for
samples above 3 fmol/L, which is in agreement with what has been reported elsewhere [16]. We also
found minimal differences in sensitivity and quantitative correlation between storage temperatures,
in line with others that compared storage at −80 ◦C to 25 ◦C [16]. However, for low-quantity samples
(i.e., 3–10 fmol/L), temperatures including 37 ◦C and changes in temperature (37/4 ◦C) may slightly
affect diagnostic sensitivity. Our environmental conditions data support the use of core-Ag from
DBS in remote regions where the sample could undergo fluctuations in storage temperature during
collection and transit.
There is notable variability in the reported sensitivity of core-Ag from DBS across studies (Table 2).
All studies included samples with diverse genotypes, and no genotype-specific changes in sensitivity
have been observed [15,16]. There are several possible reasons for the differences in sensitivity between
studies. Although each study used the Abbott core-Ag detection system, differences in collection
methods, as well as sample processing (number of spots, elution time) have not been standardized for
core-Ag processing from DBS, possibly leading to large reported differences in sensitivity ranging from
64–83% [16,20]. We showed that the sample type (venous blood vs. finger-prick) used for core-Ag
from DBS did not affect the results. Importantly, we also showed that doubling the number of spots
doubles the quantitative core-Ag results, which is relevant for samples near the limit of detection.
In our study, one sample was below the cut-off of 3000 IU/mL recommended for core-Ag testing from
serum. Thus, if we were to use the previously established HCV RNA cut-off for the core antigen assay,
our sensitivity would be 96.9% (95% CI 92.0–100%). However, in order to reliably capture sensitivity
for samples less than 1.0 × 105 IU/mL in the context of DBS, larger studies focusing on these viral loads
will need to be completed. These data will be useful to continue to standardize processing guidelines
for the microbiology diagnostics community [21].
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Table 2. Summary of sensitivity and specificity of hepatitis C virus (HCV) diagnostic options.
Test
Biondi et al. Mohamed et al. [15] Lamoury et al. [17] Soulier et al. [16] WHO Meta-Analysis [19]
Sensitivity † Specificity Sensitivity † Specificity † Sensitivity † Specificity † Sensitivity † Specificity † Sensitivity † Specificity †
HCV-Ab 98.0%(98.0–100)
100%
(100–100)
HCV RNA 100%(100–100)
99.9%
(99.5–100)
HCV-Ab DBS 100%(96.4–100)
99.1%
(97.4–99.8)
98.2%
(94.9–99.6)
98.0%
(94.0–99.0)
99.0%
(97.0–100)
HCV RNA DBS ‡ 98.1%(95.9–99.1)
100%
(97.8–100)
96.0%
(93.4–97.6)
97.7%
(94.7–99.0)
Core-Ag DBS
(−80 ◦C)
94.1%
(88.5–99.7) 15/15 76.7% 97.3%
82.9%
(74–90)
96.1%
(78–100)
64.1%
(58.5–69.3)
100%
(97.8–100)
HCV-Core-Ag DBS
(21–24 ◦C)
91.2%
(84.3–98.1) 5/5
64.1%
(58.5–69.3)
100%
(97.8–100)
† 95% CI. ‡ Combined analysis of venous and capillary blood.
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In order to work towards the global elimination of HCV, different testing methodologies will be
required. The optimal diagnostic approaches vary depending on disease prevalence, testing setting and
the availability of testing options including point-of-care antibody or HCV RNA testing, DBS collection
ability, and access to facilities for antibody, RNA, and core-Ag high-throughput sample processing [19].
Potential testing algorithms that incorporate DBS are outlined in Figure 4. The cost of both testing and
treatment may also influence the modality chosen in specific settings. With respect to DBS, a British
study looking at direct costs of HCV antibody testing from DBS versus venous sampling showed that
the cost per positive test was three times less using DBS; and other studies demonstrate that HCV RNA
DBS testing increases access to services in non-clinical settings [22–25]. Therefore, the use of DBS for
antibody screening with reflex RNA testing should be considered in areas where sample collection and
transportation are difficult (Figure 4A). Alternatively, to reduce HCV RNA testing, the use of DBS for
initial HCV-Ab screening, with a core-Ag reflex test, and a follow-up RNA test (for patients who are
HCV-Ab positive, but core-Ag negative) may also be considered in resource-rich settings (Figure 4B).
Although markedly improved in compared to other studies, the qualitative sensitivity of core-Ag
testing was still only in 91–94% range, raising concern of false-negative results if confirmatory HCV
RNA testing is not added for Ab-positive/core-Ag-negative samples (Figure 4C). Whether it would
be more cost-effective to forego confirmatory RNA testing would depend primarily on the costs of
the different assays but also on the frequency of spontaneous HCV clearance. Moreover, it must be
considered in the context of patients with very-low viral loads, as it has recently been shown that
core-Ag may not be detected [26].
In settings such as Sub-Saharan Africa, where higher rates of spontaneous HCV clearance are
reported, likely due to the high prevalence of past or current hepatitis B co-infection, more confirmatory
HCV RNA tests would be required [27–29], which is costly. Thus, as core-Ag is less expensive than
HCV RNA, it may be reasonable to first look for active infection by this method and send all negative
samples for RNA testing.
Finally, direct HCV core-Ag testing without initial Ab testing from DBS may be an appropriate
initial screening method in high prevalence populations such as in people with ongoing injection
drug use, and a less expensive alternative to HCV RNA testing (Figure 4D). However, the amount
saved by eliminating the HCV-Abs test must be weighed against the knowledge gained by knowing
an individual is antibody positive, and the potential for education or contact tracing. It should be
noted, that although predominately in early acute infection, the possibility for a patient to be HCV-Ab
negative, but RNA positive does exist. Nonetheless, a major advantage of all algorithms (Figure 4A–D)
is that additional testing can be done from the same card, reducing lost to follow-up rates before
establishing chronicity. Although additional testing could include genotyping, the relevance of this
test considering the cost, may be less important in the era of multiple pan-genotypic treatment options.
This study has important limitations. Specifically, few HCV RNA negative samples were included
and no samples post-SVR or spontaneous HCV RNA clearance were included, however, the specificity
of core-Ag testing has been well validated in many studies, as described above. Considering the small
number of samples with HCV RNA levels less than 10,000 IU/mL, it may be difficult to determine
whether the number of spots has an effect on sensitivity. However, our quantitative data clearly
demonstrate that doubling the number of spots eluted increases the amount of core-Ag detected.
In conclusion, we have demonstrated that HCV-Ab and reflex core-Ag testing from DBS has
a higher sensitivity for diagnosis (~94%) than previously reported. Quantitative DBS core-Ag level
correlates adequately to core-Ag levels in serum particularly given that the quantitative results are
of limited clinical value. We also show that HCV-Ab and core-Ag results from DBS samples are not
affected by storage temperature, as evidenced by only small differences in sensitivity, important in
situations where sample shipment can be expensive, and samples may be in transit for several days.
Finally, we demonstrate that while there is no difference between sample collection methods. There is
a linear relationship between the spot number and the quantitative HCV core-Ag result, which has the
potential to increase sensitivity of the assay if samples are slightly below the 3 fmol/L cut-off. Our data
Viruses 2019, 11, 830 11 of 14
would support using LLOD (3 fmol/L) rather than the lower limit of quantification (10 fmol/L) when
using core-Ag off DBS to improve overall sensitivity.
Our results are particularly relevant for screening in difficult-to-reach populations, where eliminating
the need for a venous sample could increase peer screening; and in rural and remote populations,
where there may be a lack of trained personnel and samples may have to undergo various temperature
changes in transit. Finally, the use of core-Ag from DBS may reduce the need for HCV RNA testing,
with the potential for cost-saving.
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Figure 4. Potential diagnostic algorithms for hepatitis C virus (HCV) testing. (A) HCV antibody testing
from DBS with subsequent RNA testing, (B) HCV antibody testing from dried blood spots (DBS) with
subsequent core-Ag testing. If core-antigen (Ag) negative, subsequent RNA testing, (C) HCV antibody
testing from DBS with subsequent core-Ag testing, (D) HCV core-Ag testing from DBS card. † Retest
as clinically indicated if suspected seroconversion or ongoing exposure. ‡ Testing ends as a result of
positive HCV core antigen. Ab = antibody, Core = core antigen, GT = genotype.
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